CHICAGO--(Organization WIRE)--Aug 30, 2022--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”), a targeted remedy, immuno-oncology business targeted on establishing opportunity to...
THIO
-Expanded clinical progress presence is expected to accelerate things to do for THIO-101 Stage 2 Demo for NSCLC- CHICAGO--(Organization WIRE)--...